Equity Profile

TECH

Bio-Techne Corporation

Health CareLife Sciences Tools & Services$11.1B

Aug5Wed

Pre-Earnings Brief

UpcomingQ4-2026Pre-Market9:00 AM EDT

Company Snapshot

Bio-Techne Corporation operates in the health care sector, focusing on life sciences tools and services. The company provides essential products and technologies that support research and development in the life sciences, making it a key player in advancing medical and scientific discoveries.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of a company's profitability, and investors will be keen to see if Bio-Techne continues its trend of beating expectations.

N/A

Revenue Growth

While specific revenue estimates are not available, growth in revenue is vital for assessing the company's market performance and operational efficiency.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TECH Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+20.74%

Avg Stock Reaction

-2.11%

Last Quarter Recap

In the last quarter, Bio-Techne reported an EPS of $0.53, surpassing expectations by 11.11%. However, the stock price dropped by 16.36% the following day, indicating market concerns despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Bio-Techne's upcoming earnings are mixed, given the company's history of beating EPS estimates but experiencing stock price volatility afterward.

Bull Case

If Bio-Techne continues its streak of EPS beats and shows strong revenue growth, it could signal robust demand for its products, leading to positive investor sentiment.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to further declines in stock price, especially given the recent volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed $0.53, indicating continued profitability?

Given the company's history of beating EPS estimates, a strong performance could bolster investor confidence.

What are the revenue growth figures compared to previous quarters?

Revenue growth is crucial for understanding market demand and the company's operational health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Bio-Techne to exceed EPS expectations based on its historical performance and product demand.

Supporting Evidence

Bio-Techne has consistently beaten EPS estimates in the past quarters, suggesting a strong operational foundation.

The options market is pricing a significant move, indicating that traders expect volatility, which could favor a positive surprise.

Key Risk

If the company reports an EPS below $0.50, it could undermine the bullish narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Bio-Techne can maintain its earnings momentum amidst recent stock price volatility.

Bull Confirmed If

An EPS of $0.55 or higher would confirm strong profitability and investor confidence.

Bear Confirmed If

An EPS below $0.50 could raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±30.67%

Historical Avg

±7.0%

Pricing rich

The options market is pricing in a significant move of about 30.67%, indicating that traders expect substantial volatility around the earnings report.

Options are pricing ±30.7% while TECH has averaged ±7.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

80.0%

Calls (15K)P/C Ratio: 0.01Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Techne beats expectations, history suggests a potential stock increase of around 6.25%, confirming strong demand.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

If the company misses expectations, history suggests a potential decline of around 2.11%, indicating market disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·3 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-MDApril McClain DelaneyRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product demand and new customer acquisitions.
2Insights into cost management and gross margin performance.
3Management's outlook on market conditions and future growth prospects.
4Details on any new product launches or innovations.
5Comments on competitive pressures and market share.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of a company's profitability, and investors will be keen to see if Bio-Techne continues its trend of beating expectations.

N/A

Revenue Growth

While specific revenue estimates are not available, growth in revenue is vital for assessing the company's market performance and operational efficiency.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TECH Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+20.74%

Avg Stock Reaction

-2.11%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Bio-Techne's upcoming earnings are mixed, given the company's history of beating EPS estimates but experiencing stock price volatility afterward.

Bull Case

If Bio-Techne continues its streak of EPS beats and shows strong revenue growth, it could signal robust demand for its products, leading to positive investor sentiment.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to further declines in stock price, especially given the recent volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed $0.53, indicating continued profitability?

Given the company's history of beating EPS estimates, a strong performance could bolster investor confidence.

What are the revenue growth figures compared to previous quarters?

Revenue growth is crucial for understanding market demand and the company's operational health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Bio-Techne to exceed EPS expectations based on its historical performance and product demand.

Supporting Evidence

Bio-Techne has consistently beaten EPS estimates in the past quarters, suggesting a strong operational foundation.

The options market is pricing a significant move, indicating that traders expect volatility, which could favor a positive surprise.

Key Risk

If the company reports an EPS below $0.50, it could undermine the bullish narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Bio-Techne can maintain its earnings momentum amidst recent stock price volatility.

Bull Confirmed If

An EPS of $0.55 or higher would confirm strong profitability and investor confidence.

Bear Confirmed If

An EPS below $0.50 could raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±30.67%

Historical Avg

±7.0%

Pricing rich

The options market is pricing in a significant move of about 30.67%, indicating that traders expect substantial volatility around the earnings report.

Options are pricing ±30.7% while TECH has averaged ±7.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

80.0%

Calls (15K)P/C Ratio: 0.01Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Techne beats expectations, history suggests a potential stock increase of around 6.25%, confirming strong demand.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

If the company misses expectations, history suggests a potential decline of around 2.11%, indicating market disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·3 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-MDApril McClain DelaneyRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product demand and new customer acquisitions.
2Insights into cost management and gross margin performance.
3Management's outlook on market conditions and future growth prospects.
4Details on any new product launches or innovations.
5Comments on competitive pressures and market share.